We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Metacrine Inc | NASDAQ:MTCR | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.4949 | 0.4601 | 0.475 | 0 | 01:00:00 |
The full list of Metacrine and partner presentations are listed below:
Poster PO-393: MET642, an FXR Agonist with a Unique Chemotype, Demonstrates a Safe, Sustained Profile in a 14-Day Randomized Study in Healthy Subjects Presentation Date and Time: June 23, 2021, 8:00 a.m. CEST
Poster PO-2388: FXR Controls Effector Cytokine Production and Phenotype in Biliary Atresia Presentation Date and Time: June 23, 2021, 8:00 a.m. CEST
Oral Presentation OS-2274: Farnesoid X Receptor Agonists Block Macrophage Derived IL1b Production, Disrupt Th1/Th17 Polarization of Effector Lymphocytes, and Ameliorate Disease Progression in Murine Sclerosing Cholangitis Presenter: Dr. Astha Malik, Research Associate, Cincinnati Children’s Hospital Medical Center Presentation Date and Time: June 25, 2021, 2:45 p.m. CEST
About Metacrine
Metacrine, Inc. is a clinical-stage biopharmaceutical company building a pipeline of differentiated therapies to treat liver and gastrointestinal diseases. Metacrine has developed a proprietary farnesoid X receptor (FXR) platform utilizing a unique chemical scaffold, which has demonstrated an improved therapeutic profile in clinical trials. The Company’s two product candidates, MET409 and MET642, are currently being investigated in clinical trials as potential new treatments for NASH. MET409 has completed a 12-week monotherapy trial in patients with NASH and is being evaluated in a 12-week combination trial with empagliflozin in patients with both NASH and type 2 diabetes. MET642 has completed a 14-day Phase 1 trial in healthy volunteers and is being evaluated in a 16-week monotherapy trial in patients with NASH. To learn more, visit www.metacrine.com.
Investor & Media Contact Steve Kunszabo Metacrine, Inc. +1 (858) 369-7892 skunszabo@metacrine.com
1 Year Metacrine Chart |
1 Month Metacrine Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions